Search
for
Sort by
Research 30 of 375
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
- IMMUNE-RELATED SKIN TOXICITIES TO CHECKPOINT INHIBITORS THERAPY
- An In Situ Chemotherapy Drug Combined with Immune Checkpoint Inhibitor for Chemoimmunotherapy
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
- The Influence of Flightless I: Regeneration versus Wound Healing
- Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
- BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Immune-Mediated Skin Reactions Induced by Recombinant Antibodies and Other TNF-Alpha Inhibitors
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Dermatologic Adverse Events from Cancer Treatments
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
- Cutaneous manifestations associated with immune checkpoint inhibitors
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Tangled Causes, Targeted Solutions: A Comprehensive Review of Alopecia.
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Regulatory T Cells: the Many Faces of Foxp3
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- Treatment options for alopecia: an update, looking to the future
- A novel therapeutic paradigm for patients with extensive alopecia areata
- The Changing Landscape of Alopecia Areata: The Translational Landscape
- Alopecia in general medicine
- Novel therapies for alopecia areata: The era of rational drug development
- Integrated single-cell chromatin and transcriptomic analyses of peripheral immune cells in patients with alopecia areata
- Current and future pharmacotherapy for alopecia areata